Davinthra Thillainathan

Stock Analyst at Goldman Sachs

(1.68)
# 3,567
Out of 4,683 analysts
36
Total ratings
40.9%
Success rate
0.5%
Average return

Stocks Rated by Davinthra Thillainathan

Australian Clinical Labs Limited
Aug 6, 2026
Downgraded: Sell
Price Target: $3.30$2.08
Current: $2.83
Upside: -26.37%
Integral Diagnostics Limited
Jun 1, 2026
Upgraded: Hold
Price Target: $2.10$2.15
Current: $2.31
Upside: -6.93%
Ansell Limited
Apr 7, 2026
Initiated Coverage: Hold
Price Target: $31.80
Current: $40.18
Upside: -20.85%
Fisher & Paykel Healthcare Corporation Limited
Feb 23, 2026
Maintained: Buy
Price Target: $51.55$53.11
Current: $44.14
Upside: +20.33%
ResMed Inc.
Feb 2, 2026
Maintained: Buy
Price Target: $49.30$53.20
Current: $32.53
Upside: +63.54%
CSL Limited
Oct 29, 2025
Maintained: Buy
Price Target: $304.60$212.10
Current: $173.10
Upside: +22.53%
Nanosonics Limited
Sep 25, 2025
Initiated Coverage: Buy
Price Target: $6.83
Current: $2.78
Upside: +145.63%
Ramsay Health Care Limited
Sep 11, 2025
Maintained: Hold
Price Target: n/a
Current: $50.60
Upside: -
Healius Limited
Aug 12, 2025
Maintained: Sell
Price Target: $1.20$0.80
Current: $0.44
Upside: n/a
Cochlear Limited
Jun 14, 2025
Maintained: Hold
Price Target: n/a
Current: $135.98
Upside: n/a
Initiated Coverage: Buy
Price Target: $32.20
Current: $20.24
Upside: n/a